BioCryst Pharmaceuticals Reports Third Quarter 2026 Financial Results

BioCryst Pharmaceuticals reported its third-quarter 2026 financial results and a corporate update, highlighting continued growth of ORLADEYO (berotralstat) and the successful launch of ORLADEYO pellets for pediatric patients. Management described the company as strongly profitable and said it is broadening its foundation for long-term success. The article provided no specific revenue, profit, growth figures, or stock-price movement.